Dr. Cathy Chang’s scientific expertise is in the areas of molecular virology, metagenomics and gene expression. Dr. Chang established and maintains BioAtla’s global laboratories, and has been head of BioAtla’s R&D Asia Operations since inception. Dr. Chang is responsible for lead discovery and development of all clinical assets at BioAtla, and she has decades of experience in management at biotechnology companies. She was formerly a Director at Synthetic Genomics, Inc. (SGI), where she was a member of the research management team and established the west coast facilities. Prior to SGI, Dr. Chang was a Director at Diversa Corporation where she led the Molecular Diversity group responsible for the discovery and recovery of novel enzymes and microorganisms from environmental samples. Prior to working at Diversa, Dr. Chang was an Associate Director at Digital Gene Technologies Inc. and a Staff Scientist at Stratagene Cloning Systems (currently Agilent), where she engineered the first mammalian cell line that could be infected by bacteriophage lambda for efficient gene delivery.
Dr. Chang earned her B.S. in Chemistry at the California Institute of Technology, and her Ph.D. in Molecular and Cellular Biology at Arizona State University. Dr. Chang received her postdoctoral training as a Damon Runyon Fellow at The Scripps Research Institute where she discovered the oncogene p3k with Dr. Peter Vogt. She is the author of more than 40 publications and patents, and received the Excellent Leadership Award while she was at Diversa.